M. Campbell

发表

System Xc− Antiporter Inhibitors: Azo-Linked Amino-Naphthyl-Sulfonate Analogues of Sulfasalazine

R. Bridges, C. Thompson, S. Patel, 2019, Neurochemical Research.

Pharmaceutical development of IPI‐504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer

Denise A. Mayes, G. Sylvester, J. Adams, 2010 .

Pharmaceutical Development of IPI-504, an Aqueous Soluble Analog of 17-AAG and Potent Inhibitor of Hsp90

G. Sylvester, E. Holson, J. Helble, 2008 .

Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists.

James R. Porter, J. Sydor, M. Foley, 2008, Journal of medicinal chemistry.

Development of a Multi Kilogram-Scale, Tandem Cyclopropanation Ring-Expansion Reaction en Route to Hedgehog Antagonist IPI-926

M. Foley, S. Peluso, J. Adams, 2016 .

Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).

Jeanne A. Ferguson, J. Sydor, J. Adams, 2009, Journal of medicinal chemistry.

First-in-class thyrotropin-releasing hormone ( TRH )-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

David J Brayden, D. Mash, O. Hardiman, 2014 .

Development of an intracellular quantitative assay to measure compound binding kinetics.

Kris D. McCombe, Kristin M. Riching, Daniel A. Thomas, 2021, Cell chemical biology.

The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway

Jeanne A. Ferguson, J. Sydor, J. Adams, 2013, Xenobiotica; the fate of foreign compounds in biological systems.

First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models

David J Brayden, D. Mash, O. Hardiman, 2015, Neuropharmacology.